ANGELA RAAB: Open Payments
NPI 1801500087 · BEL AIR, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,452 in 81 payments from 16 companies in 2025. Trend: 2023 $663 · 2024 $1,297 · 2025 $1,452
Food & beverage: $1,367Education: $85
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 12 | $240 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $183 |
| ABBVIE INC. | 11 | $170 |
| AstraZeneca Pharmaceuticals LP | 8 | $152 |
| Amgen Inc. | 13 | $151 |
| Novo Nordisk Inc | 6 | $139 |
| Lilly USA, LLC | 8 | $124 |
| PFIZER INC. | 5 | $92 |
| Exact Sciences Corporation | 2 | $62 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
Products named: Kerendia, Veozah, FARXIGA, MOUNJARO, OTEZLA, Ozempic, QULIPTA, The Cologuard Plus Collection Kit.
Industry payments across MD — which companies pay providers there.
